

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1.-20. cancelled

21. (currently amended) A method for assessing the effect of a composition or treatment on human prostate cancer, comprising:

- a) providing an immune deficient mouse comprising a human prostate cancer xenograft of locally advanced or metastatic prostate cancer tissue or a cell suspension thereof;
- b) subjecting the mouse to the composition or treatment; and,
- c) determining the effect of the composition or treatment on the growth of the xenograft in said mouse.

22. (currently amended) The method of claim 21, wherein the ~~detecting~~ determining step comprises comparing the growth of the xenograft in the mouse to the growth of the xenograft in at least another immune deficient mouse that did not receive the composition or treatment.

23. (currently amended) The method of claim 21, wherein the ~~providing step provides an immune deficient mouse bearing a subcutaneous~~ providing step provides an immune deficient mouse bearing a subcutaneous xenograft.

24. (currently amended) The method of claim 21, wherein the ~~providing step provides an immune deficient mouse bearing~~ providing step provides an immune deficient mouse bearing xenograft is an intraprostatic xenograft.

25. (currently amended) The method of claim 21, wherein the ~~providing step provides an immune deficient mouse bearing a~~ providing step provides an immune deficient mouse bearing a xenograft is within a bone marrow cavity of the mouse.

26. (currently amended) The method of claim 2 21, wherein:

a. i) the efficacy of the composition or treatment of step (b)~~subjects the xenograft mouse to a composition or treatment the efficacy of which, respectively, is not known~~
for treating human prostate cancer is not known; and,

~~b. ii)~~ step (c) determines that the treatment or composition is efficacious in impairing the growth of the human prostate cancer xenograft in the mouse.

27.-34. (cancelled)

35. (new) The method of claim 21, wherein the immune deficient mouse is a SCID mouse.